Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE.

Autoimmune diseases Autoimmunity Bioinformatics Immunology

Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
09 May 2024
Historique:
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

Applying advanced molecular profiling together with highly specific targeted therapies offers the possibility to better dissect the mechanisms underlying immune mediated inflammatory diseases such as systemic lupus erythematosus (SLE) in humans. Here we apply a combination of single cell RNA sequencing and T/B cell repertoire analysis to perform an in-depth characterization of molecular changes in the immune-signature upon CD19 CAR T cell-mediated depletion of B cells in SLE patients. The resulting datasets do not only confirm a selective CAR T cell-mediated reset of the B cell response, but simultaneously reveal consequent changes in the transcriptional signature of monocyte and T cell subsets that respond with a profound reduction in type 1 interferon signaling. Our current data thus provide evidence for a causal relationship between the B cell response and the increased interferon signature observed in SLE and additionally demonstrate the usefulness of combining targeted therapies and novel analytic approaches to decipher molecular mechanisms of immune-mediated inflammatory diseases in humans.

Identifiants

pubmed: 38722688
pii: 179433
doi: 10.1172/jci.insight.179433
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Artur Wilhelm (A)

Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

David Chambers (D)

Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Fabian Müller (F)

Department of Internal Medicine 5 - Hematology and Oncology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Aline Bozec (A)

Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Ricardo Grieshaber-Bouyer (R)

Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Thomas Winkler (T)

Department of Genetics, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Dimitrios Mougiakakos (D)

Department of Hematology, Oncology, and Stem Cell Transplantation, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

Andreas Mackensen (A)

Department of Internal Medicine 5 - Hematology and Oncology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Georg Schett (G)

Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Gerhard Krönke (G)

Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.

Classifications MeSH